Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN – Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 262,537 shares, an increase of 34.0% from the December 15th total of 195,948 shares. Based on an average daily trading volume, of 149,033 shares, the days-to-cover ratio is currently 1.8 days. Based on an average daily trading volume, of 149,033 shares, the days-to-cover ratio is currently 1.8 days.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on IINN. Wall Street Zen upgraded shares of Inspira Technologies OXY B.H.N. from a “sell” rating to a “hold” rating in a research report on Sunday, October 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inspira Technologies OXY B.H.N. in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Inspira Technologies OXY B.H.N. has a consensus rating of “Hold” and an average target price of $2.00.
Read Our Latest Stock Analysis on IINN
Inspira Technologies OXY B.H.N. Stock Performance
Institutional Trading of Inspira Technologies OXY B.H.N.
A hedge fund recently bought a new stake in Inspira Technologies OXY B.H.N. stock. Citadel Advisors LLC bought a new position in shares of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 82,567 shares of the company’s stock, valued at approximately $105,000. Citadel Advisors LLC owned 0.65% of Inspira Technologies OXY B.H.N. at the end of the most recent quarter. 12.72% of the stock is owned by institutional investors and hedge funds.
Inspira Technologies OXY B.H.N. Company Profile
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.
Read More
- Five stocks we like better than Inspira Technologies OXY B.H.N.
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Inspira Technologies OXY B.H.N. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspira Technologies OXY B.H.N. and related companies with MarketBeat.com's FREE daily email newsletter.
